Stručni rad - Pismo uredniku
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component
European Respiratory Journal, 59 (2022), 5; 2200388. https://doi.org/10.1183/13993003.00388-2022

(Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS), Tuberculosis Network European Trials group (TBnet)) Guglielmetti, Lorenzo; Günther, Gunar; Leu, Claude; Cirillo, Daniela; Duarte, Raquel; Garcia-Basteiro, Alberto L.; Goletti, Delia; Janković, Mateja; Kuksa, Liga; Maurer, Florian P.; Méchaï, Frédéric; Tiberi, Simon; van Leth, Frank; Veziris, Nicolas; Lange, Christoph Više autora...

Citirajte ovaj rad

Guglielmetti, L., Günther, G., Leu, C., Cirillo, D., Duarte, R., Garcia Basteiro, A. L. ... Lange, C. (2022). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal, 59. (5). doi: 10.1183/13993003.00388-2022

Guglielmetti, Lorenzo, et al. "Rifapentine access in Europe: growing concerns over key tuberculosis treatment component." European Respiratory Journal, vol. 59, br. 5, 2022. https://doi.org/10.1183/13993003.00388-2022

Guglielmetti, Lorenzo, Gunar Günther, Claude Leu, Daniela Cirillo, Raquel Duarte, Alberto L. Garcia Basteiro, Delia Goletti, et al. "Rifapentine access in Europe: growing concerns over key tuberculosis treatment component." European Respiratory Journal 59, br. 5 (2022). https://doi.org/10.1183/13993003.00388-2022

Guglielmetti, L., et al. (2022) 'Rifapentine access in Europe: growing concerns over key tuberculosis treatment component', European Respiratory Journal, 59(5). doi: 10.1183/13993003.00388-2022

Guglielmetti L, Günther G, Leu C, Cirillo D, Duarte R, Garcia Basteiro AL, i sur.. Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal [Internet]. 19.05.2022. [pristupljeno 18.05.2024.];59(5). doi: 10.1183/13993003.00388-2022

L. Guglielmetti, et al., "Rifapentine access in Europe: growing concerns over key tuberculosis treatment component", European Respiratory Journal, vol. 59, br. 5, Svibanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:390162. [Citirano: 18.05.2024.]